ChemoCentryx
Develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $3.7b Valuation: $3.7b 41.1x EV/Revenue | Acquisition | |
| Total Funding | 000k | ||
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (49 %) | (14 %) | 78 % | (23 %) | 84 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | 20 % | (95 %) | (147 %) | (125 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 21 % | (90 %) | (153 %) | (86 %) | (257 %) | (160 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
ChemoCentryx was founded in 1997 by Dr. Thomas Schall, a pioneer in chemokine research. The company focused on developing orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and other serious conditions. Dr. Schall's vision was to harness the power of chemokines to create targeted therapies that could address unmet medical needs.
Over the years, ChemoCentryx made significant strides in the biopharmaceutical industry, raising a total of $80.5 million over five funding rounds. The company's innovative approach and dedication to developing treatments for rare diseases caught the attention of major players in the pharmaceutical industry.
A pivotal moment in ChemoCentryx's journey came in August 2022, when Amgen, a leading biotechnology company, acquired ChemoCentryx for $3.7 billion. This acquisition marked a significant milestone for ChemoCentryx, providing the company with the resources and support needed to further its mission of developing life-changing therapies.
Today, ChemoCentryx's legacy continues under the Amgen umbrella, as it remains committed to advancing the field of biopharmaceuticals and improving the lives of patients worldwide.